547 related articles for article (PubMed ID: 22812645)
21. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
Nieschlag E; Büchter D; Von Eckardstein S; Abshagen K; Simoni M; Behre HM
Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
[TBL] [Abstract][Full Text] [Related]
22. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
von Eckardstein S; Nieschlag E
J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
[TBL] [Abstract][Full Text] [Related]
23. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
Honig S; Gittelman M; Kaminetsky J; Wang C; Amory JK; Rohowsky N; Dudley RE; Woun Seo B; Newmark J; Swerdloff R
J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
[TBL] [Abstract][Full Text] [Related]
24. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study.
Aversa A; Bruzziches R; Francomano D; Rosano G; Isidori AM; Lenzi A; Spera G
J Sex Med; 2010 Oct; 7(10):3495-503. PubMed ID: 20646185
[TBL] [Abstract][Full Text] [Related]
25. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
[TBL] [Abstract][Full Text] [Related]
26. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
27. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome.
Francomano D; Ilacqua A; Bruzziches R; Lenzi A; Aversa A
Urology; 2014 Jan; 83(1):167-73. PubMed ID: 24139347
[TBL] [Abstract][Full Text] [Related]
28. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement.
El-Sakka AI; Hassoba HM; Elbakry AM; Hassan HA
J Sex Med; 2005 Mar; 2(2):235-40. PubMed ID: 16422891
[TBL] [Abstract][Full Text] [Related]
29. Current topics in testosterone replacement of hypogonadal men.
Nieschlag E
Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):77-90. PubMed ID: 25617174
[TBL] [Abstract][Full Text] [Related]
30. A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism.
Kaminetsky JC; Moclair B; Hemani M; Sand M
J Sex Med; 2011 Apr; 8(4):1186-96. PubMed ID: 21269402
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome.
Aversa A; Bruzziches R; Francomano D; Spera G; Lenzi A
J Endocrinol Invest; 2010 Dec; 33(11):776-83. PubMed ID: 20220293
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
33. The HEAT-Registry (HEmatopoietic Affection by Testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men.
Zitzmann M; Cremers JF; Krallmann C; Kliesch S
Aging Male; 2022 Dec; 25(1):134-144. PubMed ID: 35467476
[TBL] [Abstract][Full Text] [Related]
34. Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction.
Mulhall JP; Valenzuela R; Aviv N; Parker M
Urology; 2004 Feb; 63(2):348-52; discussion 352-3. PubMed ID: 14972487
[TBL] [Abstract][Full Text] [Related]
35. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies.
Saad F; Yassin A; Doros G; Haider A
Int J Obes (Lond); 2016 Jan; 40(1):162-70. PubMed ID: 26219417
[TBL] [Abstract][Full Text] [Related]
36. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study.
Haider A; Yassin A; Haider KS; Doros G; Saad F; Rosano GM
Vasc Health Risk Manag; 2016; 12():251-61. PubMed ID: 27366080
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study.
Tan WS; Low WY; Ng CJ; Tan WK; Tong SF; Ho C; Khoo EM; Lee G; Lee BC; Lee V; Tan HM
BJU Int; 2013 Jun; 111(7):1130-40. PubMed ID: 23651425
[TBL] [Abstract][Full Text] [Related]
38. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome.
Giltay EJ; Tishova YA; Mskhalaya GJ; Gooren LJ; Saad F; Kalinchenko SY
J Sex Med; 2010 Jul; 7(7):2572-82. PubMed ID: 20524974
[TBL] [Abstract][Full Text] [Related]
39. Waist circumference is superior to weight and BMI in predicting sexual symptoms, voiding symptoms and psychosomatic symptoms in men with hypogonadism and erectile dysfunction.
Yassin AA; Nettleship JE; Salman M; Almehmadi Y
Andrologia; 2017 May; 49(4):. PubMed ID: 27400881
[TBL] [Abstract][Full Text] [Related]
40. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study.
Aversa A; Bruzziches R; Francomano D; Greco EA; Fornari R; Di Luigi L; Lenzi A; Migliaccio S
Aging Male; 2012 Jun; 15(2):96-102. PubMed ID: 22439807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
